AR Signaling and the PI3K Pathway in Prostate Cancer von Crumbaker, Megan, Khoja, Leila, Joshua, Anthony M

Volltext

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors von Chen, Sujun, Petricca, Jessica, Ye, Wenbin, Guan, Jiansheng, Zeng, Yong, Cheng, Nicholas, Gong, Linsey, Shen, Shu Yi, Hua, Junjie T., Crumbaker, Megan, Fraser, Michael, Liu, Stanley, Bratman, Scott V., van der Kwast, Theodorus, Pugh, Trevor, Joshua, Anthony M., De Carvalho, Daniel D., Chi, Kim N., Awadalla, Philip, Ji, Guoli, Feng, Felix, Wyatt, Alexander W., He, Housheng Hansen

Volltext

Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma von Bhatnagar, Atul, McKay, Matthew J., Arasaratnam, Malmaruha, Crumbaker, Megan, Gurney, Howard, Molloy, Mark P.

Volltext

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT) von Emmett, Louise, John, Nikeith, Pathmanandavel, Sarennya, Counter, William, Ayers, Maria, Sharma, Shikha, Agrawal, Shikha, Poole, Aron, Hovey, Elizabeth, Pranavan, Ganes, Gedye, Craig, Mallesara, Girish, Guminski, Alex, Lee, Adrian, Stockler, Martin R., Hickey, Adam, Eu, Peter, Joshua, Anthony M., Crumbaker, Megan, Nguyen, Andrew

Volltext

Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients von Bhatnagar, Atul, McKay, Matthew J., Thaysen-Andersen, Morten, Arasaratnam, Malmaruha, Crumbaker, Megan, Gurney, Howard, Molloy, Mark P.

Volltext

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer von Mak, Blossom, Lin, Hui-Ming, Kwan, Edmond M, Fettke, Heidi, Tran, Ben, Davis, Ian D, Mahon, Kate, Stockler, Martin R, Briscoe, Karen, Marx, Gavin, Zhang, Alison, Crumbaker, Megan, Tan, Winston, Huynh, Kevin, Meikle, Thomas G, Mellett, Natalie A, Hoy, Andrew J, Du, Pan, Yu, Jianjun, Jia, Shidong, Joshua, Anthony M, Waugh, David J, Butler, Lisa M, Kohli, Manish, Meikle, Peter J, Azad, Arun A, Horvath, Lisa G

Volltext

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer von Lin, Hui-Ming, Yeung, Nicole, Hastings, Jordan F., Croucher, David R., Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Davis, Ian D., Tran, Ben, Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Bastick, Patricia, Crumbaker, Megan L., Joshua, Anthony M., Azad, Arun A., Meikle, Peter J., Horvath, Lisa G.

Volltext

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase von Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., Horvath, Lisa G.

Volltext

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617 von Crumbaker, Megan, Goldstein, Leonard D., Murray, David H., Tao, Jiang, Pathmanandavel, Sarennya, Boulter, Nicky, Ratnayake, Lalith, Joshua, Anthony M., Kummerfeld, Sarah, Emmett, Louise

Volltext

Reply: Unraveling the Hypocalcemic Response to 177 Lu-Prostate-Specific Membrane Antigen Therapy von Kumar, Shejil, Crumbaker, Megan, Emmett, Louise

Volltext

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (... von Conduit, Ciara, Mak, Blossom, Qu, Wenjia, Lulio, Juliana Di, Burder, Ronan, Bressel, Matthias, Cusick, Thomas, Dhillon, Haryana M., Lourenço, Richard De Abreu, Underhill, Craig, Torres, Javier, Crumbaker, Megan, Honeyball, Florian, Linton, Anthony, Allen, Ray, Davis, Ian D., Clark, Susan J., Horvath, Lisa G., Mahon, Kate L.

Volltext

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue von Nguyen, Linh T., Lo, Charlotte S., Fyrsta, Michael, Nie, Jessica, Yam, Jennifer Y., Yen, Pei-Hua, Le, Michael X., Hersey, Karen, Kenk, Miran, Crumbaker, Megan, Fleshner, Neil, Kulkarni, Girish, Hamilton, Robert, Jewett, Michael, Finelli, Antonio, Evans, Andrew, Sweet, Joan, Ohashi, Pamela S., Joshua, Anthony M.

Volltext

Dose considerations for anti‐cancer drugs in metastatic prostate cancer von Crumbaker, Megan, Gurney, Howard

Volltext

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Pa... von Emmett, Louise, Crumbaker, Megan, Ho, Bao, Willowson, Kathy, Eu, Peter, Ratnayake, Lalith, Epstein, Richard, Blanksby, Ashley, Horvath, Lisa, Guminski, Alex, Mahon, Kate, Gedye, Craig, Yin, Charlotte, Stricker, Phillip, Joshua, Anthony M.

Volltext

Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen Therapy\Reply: Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen The... von Askari, Emran, Harsini, Sara, Kumar, Shejil, Crumbaker, Megan, Emmett, Louise

Volltext

Reply: Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen Therapy von Kumar, Shejil, Crumbaker, Megan, Emmett, Louise

Volltext

Patient Preference or Indifference: Learning from the CABADOC Study von Joshua, Anthony M., Gurney, Howard, Dhillon, Haryana M., Crumbaker, Megan

Volltext

Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 t... von Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, Davis, Ian D

Volltext

Development of a Visually Calculated SUV mean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177 Lu-PSMA Therapy: Comparison with Quantitative SUV mean and P... von Swiha, Mina, Papa, Nathan, Sabahi, Zahra, Ayati, Narjess, John, Nikeith, Pathmanandavel, Sarennya, Crumbaker, Megan, Li, Sherrington, Agrawal, Shikha, Ayers, Maria, Hickey, Adam, Sharma, Shikha, Nguyen, Andrew, Emmett, Louise

Volltext

A phase I study of 177 Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial) von Crumbaker, Megan, Joshua, Anthony M., Epstein, Richard, Emmett, Louise

Volltext